TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| ViraCor-IBT develops swine flu test A local laboratory said Monday that it has developed a test to diagnose the H1N1, or swine, flu in patients. feeds.bizjournals.com |
Cel-Sci's Positive Momentum Keeps Building For years, it seems, CEL-SCI's (CVM) investors have been waiting for this perfect storm of positive developments. The company was so badly beaten and on the ropes recently, that most of the management team continued to work, for extended periods of time, without compensation. "When I came home and told my wife about the pay cut, she looked at me as if I was crazy," says CEL-SCI's CEO, Geert Kersten.Complete Story » seekingalpha.com |
October FDA Calendar Stocks: Tricks or Treats? Mike Havrilla submits:Below are six stocks from the BioMedReports.com FDA Calendar with expected catalysts during the month of October, including three pending FDA decisions, updated clinical trial data, and an expected FDA filing to expand the label of an existing product (sNDA). On 8/13/09, BioSante Pharma (NASDAQ: BPAX) announced positive safety data in its ongoing LibiGel Phase 3 clinical development program, reporting that with over 1,250 women enrolled and almost 825 women-years of exposure in its LibiGel Phase 3 program, there have been no deaths and only five cardiovascular events. This analysis of blinded data indicates a very low cardiovascular event rate has occurred thus far and the studies will continue as planned. BPAX targets submission to the FDA of a new drug application (NDA) by mid-2011. Complete Story » seekingalpha.com |
FDA to Look at New Type of Flu Vaccine An FDA panel will meet next week to consider a new type of vaccine that's made without relying on old technology that employs chicken eggs to grow viruses used for flu shots. online.wsj.com |
Sanofi-Aventis to Buy Chattem French drug maker Sanofi-Aventis stepped up its move into consumer drugs by entering the U.S. market, acquiring Chattem for $1.9 billion. online.wsj.com |